Recent Updates
Recently added Catalysts
SVRA Negative Sentiment Score: 25/100

Savara Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SVRA

Key Takeaway: Savara Inc. is facing a class action lawsuit for securities law violations related to its treatment for pulmonary alveolar proteinosis, MOLBREEVI. The claims suggest that the company made false statements regarding the drug's regulatory status and its potential approval timeline. Investors are being encouraged to register for participation in the lawsuit, which addresses concerns about the adequacy of Savara's disclosures and the potential need for additional capital. The deadline for shareholders to seek lead plaintiff status is set for November 7, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • Savara Inc. is facing allegations of issuing materially false and misleading statements.
  • Concerns over the approval of MOLBREEVI due to insufficient information regarding its chemistry and manufacturing.
  • The lack of clarity from Savara may delay the BLA submission and increase the need for additional capital.
  • The allegations could negatively impact investor confidence and stock performance.

Full Press Release Details

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA).
Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 4, 2024 to May 23, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) MOLBREEVI BLA, the treatment of pulmonary alveolar proteinosis, lacked sufficient information regarding MOLBREEVI’s chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv) delay in MOLBREEVI’s regulatory approval increased the likelihood that the Company would need to raise additional capital; and (v) as a result, defendants’ public statements were materially false and misleading at all relevant times.
DEADLINE: November 7, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/savara-inc-loss-submission-form/?id=169625&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SVRA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is November 7, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for the Savara Inc. allegations?

The class period for the allegations is from March 4, 2024, to May 23, 2025.

What were the claims against Savara Inc.?

Claims include misleading statements about MOLBREEVI BLA's approval likelihood and potential delays.

When is the deadline to register as a lead plaintiff?

The deadline to seek lead plaintiff status is November 7, 2025.

How can shareholders monitor their case status?

Registered shareholders will receive status updates through portfolio monitoring software.

Is there a cost to participate in the class action?

There is no cost or obligation to participate in the case.

Last updated: Sep 29, 2025